BRAF and lung carcinoma: For these reasons, the oncogenic RAF-MAPK axis is nowadays used as a target for cancer therapies and specific BRAF and MEK inhibitors have been now approved by FDA (US Food and Drug Administration) for the treatment of diseases such as melanoma and lung cancer [19, 20].